Similarities and Differences Between Primary and Secondary Degeneration of the Optic Nerve and the Effect of Minocycline

Overview

Journal Graefes Arch Clin Exp Ophthalmol

Specialty Ophthalmology

Date 2011 Jan 14

PMID 21229256

Citations 16

Authors

Hani Levkovitch-Verbin

Oriel Spierer

Shelly Vander

Rima Dardik

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate the mechanism of secondary degeneration of the optic nerve, and to evaluate the neuroprotective effect of minocycline in this process.

Methods: A partial transection model that morphologically separates primary and secondary degeneration was applied unilaterally in 152 Wistar rat eyes. The involvement of pro-apoptotic, pro-survival and inflammatory pathways was analyzed by quantitative real-time PCR and immunohistochemistry at multiple time points. The neuroprotective effect of daily intraperitoneal injections of minocycline 22 mg/kg/day was evaluated at 7, 11 and 21 days post-injury. Retrograde labeling of retinal ganglion cells (RGCs) with fluorogold was via the superior colliculus, and surviving RGCs were counted using retinal whole mounts.

Results: Both primary and secondary degeneration led to a significant up-regulation of the pro-apoptotic genes, GADD45α, ei24 and CDK2, and the pro-survival gene, IAP-1. These processes differed, however, in their reaction to minocycline. Minocycline protected RGC death from secondary degeneration at 11 days (6 ± 8% loss compared to 37 ± 7% in the saline-treated group, n = 15, P = 0.012), and at 21 days (42 ± 7% versus 64 ± 7% respectively, n = 15, P = 0.06) after partial transection. In contrast, its effect on primary degeneration was not significant.

Conclusions: While the genetic profile supported similarities between primary and secondary degeneration of the optic nerve, the specific effect of minocycline on secondary degeneration revealed a potential difference between the two. The mechanism underlying secondary degeneration, and its role in optic neuropathies such as glaucoma, awaits further studies.

Citing Articles

Secondary Degeneration Impairs Myelin Ultrastructural Development in Adulthood following Adolescent Neurotrauma in the Rat Optic Nerve.

Lins B, Anyaegbu C, McGonigle T, Hellewell S, Patel P, Reagan H Int J Mol Sci. 2023; 24(4).

PMID: 36834755 PMC: 9966883. DOI: 10.3390/ijms24043343.

Gadd45 in Neuronal Development, Function, and Injury.

Sultan F, Sawaya B Adv Exp Med Biol. 2022; 1360:117-148.

PMID: 35505167 DOI: 10.1007/978-3-030-94804-7_9.

Insulin Signaling as a Therapeutic Target in Glaucomatous Neurodegeneration.

Al Awamlh S, Wareham L, Risner M, Calkins D Int J Mol Sci. 2021; 22(9).

PMID: 33925119 PMC: 8124776. DOI: 10.3390/ijms22094672.

Dimethyl Fumarate Promotes the Survival of Retinal Ganglion Cells after Optic Nerve Injury, Possibly through the Nrf2/HO-1 Pathway.

Mori S, Kurimoto T, Maeda H, Nakamura M Int J Mol Sci. 2021; 22(1).

PMID: 33396673 PMC: 7795407. DOI: 10.3390/ijms22010297.

Quantitative profiling of regional protein expression in rat retina after partial optic nerve transection using fluorescence difference two‑dimensional gel electrophoresis.

Lam C, Li K, Do C, Chan H, To C, Kwong J Mol Med Rep. 2019; 20(3):2734-2742.

PMID: 31524249 PMC: 6691257. DOI: 10.3892/mmr.2019.10525.

References

Levkovitch-Verbin H, Kalev-Landoy M, Habot-Wilner Z, Melamed S . Minocycline delays death of retinal ganglion cells in experimental glaucoma and after optic nerve transection. Arch Ophthalmol. 2006; 124(4):520-6. DOI: 10.1001/archopht.124.4.520. View

Zhang Y, Metz L, Yong V, Bell R, Yeung M, Patry D . Pilot study of minocycline in relapsing-remitting multiple sclerosis. Can J Neurol Sci. 2008; 35(2):185-91. DOI: 10.1017/s0317167100008611. View

Libby R, Li Y, Savinova O, Barter J, Smith R, Nickells R . Susceptibility to neurodegeneration in a glaucoma is modified by Bax gene dosage. PLoS Genet. 2005; 1(1):17-26. PMC: 1183523. DOI: 10.1371/journal.pgen.0010004. View

Chen M, Ona V, Li M, Ferrante R, Fink K, Zhu S . Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000; 6(7):797-801. DOI: 10.1038/77528. View

Yuan L, Neufeld A . Activated microglia in the human glaucomatous optic nerve head. J Neurosci Res. 2001; 64(5):523-32. DOI: 10.1002/jnr.1104. View

Martin-Villalba A, Herr I, Jeremias I, Hahne M, Brandt R, Vogel J . CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons. J Neurosci. 1999; 19(10):3809-17. PMC: 6782733. View

Bosco A, Inman D, Steele M, Wu G, Soto I, Marsh-Armstrong N . Reduced retina microglial activation and improved optic nerve integrity with minocycline treatment in the DBA/2J mouse model of glaucoma. Invest Ophthalmol Vis Sci. 2008; 49(4):1437-46. DOI: 10.1167/iovs.07-1337. View

Tezel G, Yang X, Yang J, Wax M . Role of tumor necrosis factor receptor-1 in the death of retinal ganglion cells following optic nerve crush injury in mice. Brain Res. 2003; 996(2):202-12. DOI: 10.1016/j.brainres.2003.10.029. View

Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J . Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A. 1998; 95(26):15769-74. PMC: 28119. DOI: 10.1073/pnas.95.26.15769. View

10.

Rideout H, Wang Q, Park D, Stefanis L . Cyclin-dependent kinase activity is required for apoptotic death but not inclusion formation in cortical neurons after proteasomal inhibition. J Neurosci. 2003; 23(4):1237-45. PMC: 6742273. View

11.

Ju K, Kim H, Kim J, Lee N, Park C . Retinal glial cell responses and Fas/FasL activation in rats with chronic ocular hypertension. Brain Res. 2006; 1122(1):209-21. DOI: 10.1016/j.brainres.2006.09.022. View

12.

Baptiste D, Powell K, Jollimore C, Hamilton C, LeVatte T, Archibald M . Effects of minocycline and tetracycline on retinal ganglion cell survival after axotomy. Neuroscience. 2005; 134(2):575-82. DOI: 10.1016/j.neuroscience.2005.04.011. View

13.

Tezel G, Li L, Patil R, Wax M . TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes. Invest Ophthalmol Vis Sci. 2001; 42(8):1787-94. View

14.

Martin-Villalba A, Hahne M, Kleber S, Vogel J, Falk W, Schenkel J . Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death Differ. 2001; 8(7):679-86. DOI: 10.1038/sj.cdd.4400882. View

15.

Levkovitch-Verbin H, Dardik R, Vander S, Nisgav Y, Kalev-Landoy M, Melamed S . Experimental glaucoma and optic nerve transection induce simultaneous upregulation of proapoptotic and prosurvival genes. Invest Ophthalmol Vis Sci. 2006; 47(6):2491-7. DOI: 10.1167/iovs.05-0996. View

16.

Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G . A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry. 2009; 71(2):138-49. DOI: 10.4088/JCP.08m04666yel. View

17.

Naskar R, Wissing M, Thanos S . Detection of early neuron degeneration and accompanying microglial responses in the retina of a rat model of glaucoma. Invest Ophthalmol Vis Sci. 2002; 43(9):2962-8. View

18.

Yang Z, Quigley H, Pease M, Yang Y, Qian J, Valenta D . Changes in gene expression in experimental glaucoma and optic nerve transection: the equilibrium between protective and detrimental mechanisms. Invest Ophthalmol Vis Sci. 2007; 48(12):5539-48. DOI: 10.1167/iovs.07-0542. View

19.

Chauhan B, LeVatte T, Jollimore C, Yu P, Reitsamer H, Kelly M . Model of endothelin-1-induced chronic optic neuropathy in rat. Invest Ophthalmol Vis Sci. 2003; 45(1):144-52. DOI: 10.1167/iovs.03-0687. View

20.

Levkovitch-Verbin H, Dardik R, Vander S, Melamed S . Mechanism of retinal ganglion cells death in secondary degeneration of the optic nerve. Exp Eye Res. 2009; 91(2):127-34. DOI: 10.1016/j.exer.2009.11.014. View